Voyager Acquisition Corp./Cayman Islands
VACHDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
May 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
VP4896
Alzheimer's Disease
Leuprolide acetate
Alzheimer Disease
VY7523
Alzheimer's Disease (AD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VP4896 | Phase 3 | Alzheimer's Disease | - | - |
Leuprolide acetate | Phase 2 | Alzheimer Disease | - | - |
VY7523 | Phase 2 | Alzheimer's Disease (AD) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Voyager Acquisition Corp./Cayman Islands's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Voyager Acquisition Corp./Cayman Islands's (VACH) pipeline across Phase 3, Phase 2. Its lead program is VP4896 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Voyager Acquisition Corp./Cayman Islands's next FDA catalyst?→
Voyager Acquisition Corp./Cayman Islands's (VACH) next tracked catalyst is a Phase 2 expected May 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VACH biotech catalysts?→
Add VACH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Voyager Acquisition Corp./Cayman Islands's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.